



Atty. Dkt. No.	C-M#	Client Ref.
	068800-0284057	206002/JND/nlb
Applicant: PEPYS		
Appln. No.: 09/985,699		
Filing Date: November 5, 2001		
Examiner: MELLER, M.V.		Group Art Unit: 1654

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: September 5, 2003 Page 1 of 2

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
MM	AR1	EP 0915088	05/1999	EUROPE				
MM	BR1	WO 9746098	12/1997	WIPO				

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MM	CR1	PCT search report PCT/GB 02/03504						
MM	DR1	Lindorfer <i>et al.</i> , "A bispecific dsDNA monoclonal antibody construct for clearance of anti-dsDNA IGG in systemic lupus erythematosus", <i>J. Immunol. Methods</i> 248 , 125-138, 2001.						
	ER1	Riedstra <i>et al.</i> , "Study of an anti-human transthyretin immunoabsorbent - influence of coupling chemistry on binding capacity and ligand leakage", <i>J. Chromatogr. B: Biomedical Sciences & Applications</i> . 705(2) , 213-222, 1998.						
	FR1	Paul <i>et al.</i> , "Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates", <i>Bioorg. Med. Chem. Lett.</i> 10(18) , 2149-2152, 2000.						
	GR1	Cleaveland <i>et al.</i> , "Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program", <i>Biochem. Pharmacol.</i> 49(7) , 947-954, 1995.						
	HR1	Purkey <i>et al.</i> , "Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma", <i>Proc. Natl. Acad. Sci. USA</i> 98(10) , 5566-5571, 2001.						
	IR1	Pepys <i>et al.</i> , "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis", <i>Nature</i> 417 , 254-259, 2002.						
	JR1	Hind <i>et al.</i> , "Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits", <i>Lancet</i> , 376-378, 1984.						
	KR1	Tennent <i>et al.</i> , "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis", <i>Proc. Natl. Acad. Sci. USA</i> 92 , 299-4303, 1995.						
	LR1	Pepys <i>et al.</i> , "Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy", <i>The Nature and Origin of Amyloid Fibrils</i> , 73-89, 1996.						
	MR1	Pepys <i>et al.</i> , "Amyloid P component. A critical review.", <i>Int. J. Exp. Clin. Invest.</i> 4 , 274-295, 1997.						
	NR1	Pepys, "C-reactive protein and amyloidosis: from protein to drugs?", <i>The Lumleian Lecture</i> , 397-414.						
	OR1	Nelson <i>et al.</i> , "Serum amyloid P component in chronic renal failure and dialysis", <i>Clinica Chimica Acta</i> 200 , 191-200, 1991.						
	PR1	Booth <i>et al.</i> , "Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis", <i>Nature</i> 385 , 787-793, 1997.						
	QR1	Pepys <i>et al.</i> , "Human lysozyme gene mutations cause hereditary systemic amyloidosis", <i>Nature</i> 362 , 553-557, 1993.						
	RR1	Purkey <i>et al.</i> , "Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma", <i>Proc. Natl. Acad. Sci. USA</i> 98(10) , 5566-5571, 2001.						

Examiner	Date Considered:
MM	9/21/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty. Dkt. No.	C-M#	Client Ref.
	068800-0284057	206002/JND/nlb

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: PEPYS
Appln. No.: 09/985,699
Filing Date: November 5, 2001
Examiner: MELLER, M.V. Group Art Unit: 1654

Date: September 5, 2003 Page 2 of 2

Examiner's Initials*							Enclosed	No	Enclosed	No
-------------------------	--	--	--	--	--	--	----------	----	----------	----

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SR1	Holmgren <i>et al.</i> , "Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met ³⁰), <i>Clin. Genet.</i> 40 , 242-246, 1991.			
TR1	Pepys <i>et al.</i> , "Isolation of amyloid P component (Protein AP) from normal serum as a calcium-dependent binding protein", <i>Lancet</i> , 1029-1031, 1977.			
UR1	Pontet <i>et al.</i> , "One step preparation of both human C-reative protein and Cit", <i>FEBS Letters</i> 88(2) , 172-175, 1978.			
VR1	Hind <i>et al.</i> , "Binding specificity of serum amyloid P component for the pyruvate acetal of galactose", <i>J. Exp. Med.</i> 159 , 1058-1069, 1984.			
WR1	Emsley <i>et al.</i> , "Structure of pentameric human serum amyloid P component", <i>Nature</i> 367 , 338-345, 1994.			
XR1	Hohenester <i>et al.</i> , "Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP", <i>J. Mol. Biol.</i> 269 , 570-578, 1997.			
YR1	Ashton <i>et al.</i> , "Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses", <i>J. Mol. Biol.</i> 272 , 408-422, 1997.			
ZR1	Baltz <i>et al.</i> , "Calcium-dependent aggregation of human serum amyloid P component", <i>Biochim. Biophys. Acta</i> 701 , 229-236, 1982.			
AR2	Booth <i>et al.</i> , "Analysis of autoaggregation and ligand binding sites of serum amyloid P component by in vitro mutagenesis", <i>Amyloid and Amyloidosis 1998</i> , 23-25, 1998.			
BR2	Hutchinson <i>et al.</i> , "Human serum amyloid P component is a single uncomplexed pentamer in whole serum", <i>Mol. Med.</i> 6(6) , 482-493, 2000.			
CR2	Hawkins <i>et al.</i> , "Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis", <i>J. Clin. Invest.</i> 86 , 1862-1869, 1990.			
DR2	Hutchinson <i>et al.</i> , "The petraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes <i>in vivo</i> ", <i>J. Clin. Invest.</i> 94 , 1390-1396, 1994.			
ER2	Pepys <i>et al.</i> , "Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure", <i>Proc. Natl. Acad. Sci. USA</i> 91 , 5602-5606, 1994.			
FR2	Holmgren <i>et al.</i> , "Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis", <i>Lancet</i> , 1113-1116, 1993.			
GR2	Klabunde <i>et al.</i> , "Rational design of potent human transthyretin amyloid disease inhibitors", <i>Nature Struct. Biol.</i> 7(4) , 312-321, 2000.			

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.